Delving into the Latest Updates on 成都景润泽基因科技有限公司 with Synapse

概览

疾病领域	数量

神经系统疾病	1

排名前五的药物类型	数量

miRNA	1
siRNA	1
酶	1

排名前五的靶点	数量

miR-22	1
PLG(纤溶酶原)	1

关联

5

项与成都景润泽基因科技有限公司相关的药物

JZB-32

重组人截短型纤溶酶(景泽生物)

靶点

PLG

作用机制

PLG刺激剂

在研机构

成都景泽生物制药有限公司 [+2]

原研机构

成都景泽生物制药有限公司

在研适应症

息肉状脉络膜血管病 [+1]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

tFNA-miR22

靶点

miR-22

作用机制

miR-22抑制剂

在研机构

成都景润泽基因科技有限公司

原研机构

成都景润泽基因科技有限公司

在研适应症

视神经疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

TDNs-siRNA

靶点-

作用机制-

在研机构

成都景润泽基因科技有限公司

原研机构

成都景润泽基因科技有限公司

在研适应症

视网膜疾患

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

1

项与成都景润泽基因科技有限公司相关的临床试验

CTR20234091 / Recruiting临床1期

一项多中心、开放、单次给药剂量递增的重组人截短型纤溶酶（JZB32）注射液治疗息肉样脉络膜血管病变的 I 期临床试验

探索息肉样脉络膜血管病变（PCV）受试者玻璃体腔单次注射 JZB32 后的安全性，确定最大耐受剂量（MTD），及用于 II 期临床试验的推荐剂量（RP2D）

开始日期2024-08-19

申办/合作机构

成都景泽生物制药有限公司

[+1]

100 项与成都景润泽基因科技有限公司相关的临床结果

登录后查看更多信息

0 项与成都景润泽基因科技有限公司相关的专利（医药）

登录后查看更多信息

2

项与成都景润泽基因科技有限公司相关的文献（医药）

2024-04-01·International Journal of Biological Macromolecules

Cm-siRPred: Predicting chemically modified siRNA efficiency based on multi-view learning strategy

Article

作者: Ning, Lin ; Lin, Hao ; Zhang, Yang ; Ren, Liping ; Huang, Jian ; Luo, Delun ; Huang, Junyang ; Liu, Tianyuan

The rational modification of siRNA molecules is crucial for ensuring their drug-like properties. Machine learning-based prediction of chemically modified siRNA (cm-siRNA) efficiency can significantly optimize the design process of siRNA chemical modifications, saving time and cost in siRNA drug development. However, existing in-silico methods suffer from limitations such as small datasets, inadequate data representation capabilities, and lack of interpretability. Therefore, in this study, we developed the Cm-siRPred algorithm based on a multi-view learning strategy. The algorithm employs a multi-view strategy to represent the double-strand sequences, chemical modifications, and physicochemical properties of cm-siRNA. It incorporates a cross-attention model to globally correlate different representation vectors and a two-layer CNN module to learn local correlation features. The algorithm demonstrates exceptional performance in cross-validation experiments, independent dataset, and case studies on approved siRNA drugs, and showcasing its robustness and generalization ability. In addition, we developed a user-friendly webserver that enables efficient prediction of cm-siRNA efficiency and assists in the design of siRNA drug chemical modifications. In summary, Cm-siRPred is a practical tool that offers valuable technical support for siRNA chemical modification and drug efficiency research, while effectively assisting in the development of novel small nucleic acid drugs. Cm-siRPred is freely available at https://cellknowledge.com.cn/sirnapredictor/.

2022-12-01·International Journal of Oral Science

Advances in regenerative medicine applications of tetrahedral framework nucleic acid-based nanomaterials: an expert consensus recommendation

Review

作者: Wang, Lihua ; Tian, Xudong ; Li, Haihang ; Lin, Yunfeng ; Li, Qian ; Guo, Quanyi ; Luo, Delun ; Shi, Sirong ; Liu, Shuyun ; Sun, Yong ; Zhu, Shihui ; Fan, Yujiang ; Sun, Yu

AbstractWith the emergence of DNA nanotechnology in the 1980s, self-assembled DNA nanostructures have attracted considerable attention worldwide due to their inherent biocompatibility, unsurpassed programmability, and versatile functions. Especially promising nanostructures are tetrahedral framework nucleic acids (tFNAs), first proposed by Turberfield with the use of a one-step annealing approach. Benefiting from their various merits, such as simple synthesis, high reproducibility, structural stability, cellular internalization, tissue permeability, and editable functionality, tFNAs have been widely applied in the biomedical field as three-dimensional DNA nanomaterials. Surprisingly, tFNAs exhibit positive effects on cellular biological behaviors and tissue regeneration, which may be used to treat inflammatory and degenerative diseases. According to their intended application and carrying capacity, tFNAs could carry functional nucleic acids or therapeutic molecules through extended sequences, sticky-end hybridization, intercalation, and encapsulation based on the Watson and Crick principle. Additionally, dynamic tFNAs also have potential applications in controlled and targeted therapies. This review summarized the latest progress in pure/modified/dynamic tFNAs and demonstrated their regenerative medicine applications. These applications include promoting the regeneration of the bone, cartilage, nerve, skin, vasculature, or muscle and treating diseases such as bone defects, neurological disorders, joint-related inflammatory diseases, periodontitis, and immune diseases.

100 项与成都景润泽基因科技有限公司相关的药物交易

登录后查看更多信息

100 项与成都景润泽基因科技有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

1

临床1期

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

重组人截短型纤溶酶(景泽生物) ( PLG )	息肉状脉络膜血管病更多	临床1期
tFNA-miR22 ( miR-22 )	视神经疾病更多	临床前
TDNs-siRNA	视网膜疾患更多	临床前
DNA四面体	角膜损伤更多	无进展
tFNA-miR155 ( miR-155 )	湿性黄斑变性更多	无进展